Oppenheimer analyst Leland Gershell maintains $argenx SE (ARGX.US)$ with a buy rating, and adjusts the target price from $646 to $675.
According to TipRanks data, the analyst has a success rate of 36.0% and a total average return of 1.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
The decision to proceed to Phase 3 across all three myositis subtypes has been recognized as an encouraging development that enhances the future value of the pipeline, though it may not significantly impact stock levels immediately. The firm has updated its model to reflect a 70% likelihood of success for myositis, with provisions to modify this estimate upon reviewing comprehensive data at an upcoming medical conference.
Argenx has demonstrated clinical proof-of-concept in myositis, with its subQ efgart treatment showing statistically significant improvements across all three myositis subtypes being evaluated in Phase 2. Detailed results are anticipated to be presented at a future medical meeting. This development is considered to extend Argenx's influence in the autoimmune sector.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Leland Gershell維持$argenx SE (ARGX.US)$買入評級，並將目標價從646美元上調至675美元。
根據TipRanks數據顯示，該分析師近一年總勝率為36.0%，總平均回報率為1.1%。
此外，綜合報道，$argenx SE (ARGX.US)$近期主要分析師觀點如下：
決定在所有三種肌炎亞型中進入第3階段被視爲一個鼓舞人心的進展，這增強了未來的管線價值，儘管這可能不會立即對股價產生重大影響。公司已經更新了其模型，以反映肌炎的成功概率爲70%，並在即將召開的醫療會議上審查全面數據時準備修改這一估計。
Argenx在肌炎方面展示了臨床概念的證據，subQ efgart治療在評估的三種肌炎亞型中的效果具有統計學顯著性，顯示出顯著改善。詳細結果預計將在未來的醫療會議上進行介紹。該進展被視爲擴大Argenx在自身免疫板塊的影響。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
